Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Egypt.
Department of Medical Oncology, Faculty of Medicine, Mansoura University, Egypt.
Asian Pac J Cancer Prev. 2023 Mar 1;24(3):969-975. doi: 10.31557/APJCP.2023.24.3.969.
Currently, it is well recognized that response to neoadjuvant chemotherapy is an important predictive factor for survival in breast cancer patients. However, it is still an area of research about which patient would respond to the neoadjuvant chemotherapy.
Serum CK18 levels were measured using ELISA from 52 newly diagnosed breast cancer patients, at presentation and after first cycle of neo-adjuvant chemotherapy. Pre- and post-treatment CK-18 levels were correlated with several clinical and pathological parameters. At the end of neoadjuvant treatment, changes in serum CK18 levels were correlated with tumors' response to therapy.
Significant elevation of pre-chemotherapy CK18 level was observed in patients who had progressive disease compared to those who had complete or partial response to therapy (P=0.006 and P<0.001, respectively). Significantly higher CK18 levels were observed post-chemotherapy in complete and partial responders, in contrast to patients with stable or progressive disease (P=0.012% and P=0.001%, respectively). The percent of change was significantly higher in complete responders compared to patients who had stable or progressive disease (P=0.043% and P=0.045%, respectively).
Our results suggest that patients with increasing CK18 level following chemotherapy are potential responders to their neoadjuvant protocol. Thus, the measurement of serum CK18 early in the treatment course could be a simple, noninvasive way to predict tumor response to neoadjuvant chemotherapy.
目前，人们已经充分认识到，新辅助化疗的疗效是乳腺癌患者生存的重要预测因素。然而，对于哪些患者会对新辅助化疗产生反应，这仍然是一个研究领域。
从 52 名新诊断的乳腺癌患者中，在就诊时和新辅助化疗第一周期后，使用 ELISA 法测量血清 CK18 水平。治疗前后 CK-18 水平与多个临床和病理参数相关。在新辅助治疗结束时，血清 CK18 水平的变化与肿瘤对治疗的反应相关。
与完全或部分缓解的患者相比，疾病进展的患者化疗前 CK18 水平显著升高（P=0.006 和 P<0.001）。完全和部分缓解的患者化疗后 CK18 水平明显升高，而稳定或进展的患者则不然（P=0.012% 和 P=0.001%）。完全缓解的患者比稳定或进展的患者的变化百分比明显更高（P=0.043% 和 P=0.045%）。
我们的研究结果表明，化疗后 CK18 水平升高的患者可能对新辅助方案有反应。因此，在治疗过程早期测量血清 CK18 可能是一种简单、非侵入性的方法，用于预测肿瘤对新辅助化疗的反应。
